KRAS and colorectal cancer: The 5‐year colorectal cancer‐specific survival probabilities were 81% in KRAS‐wild‐type patients, 66% in KRAS c.34G>T (p.G12C)‐mutated patients, and 71% in other KRAS‐mutated patients (Figure 2).